Virginia 2022 Regular Session Status: Enacted

SB 759 — Drug Control Act; adds certain chemicals to the Act.

Last action — Approved by Governor-Chapter 115 (effective 7/1/22)

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. ✓
    Passed Senate
  4. ✓
    Passed House of Delegates
  5. ✓
    To Executive
  6. 6
    Enacted

This bill has been enacted into law. Introduced January 21, 2022. Enacted.

Signed by Governor Glenn Youngkin (Republican) on April 06, 2022.

Prognosis

Likely to advance 70% · moderate confidence

Where this bill stands today.

Odds of enactment

High

How often bills like it became law.

  • Enacted

    Current position in the legislative process.

  • 1 sponsor

    1 primary, 0 co-sponsors signed on.

  • Cleared a recorded vote

    Passed 7 recorded votes so far.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Summary

Drug Control Act; Schedule I; Schedule II; Schedule IV; Schedule V. Adds certain chemicals to the Drug Control Act. The Board of Pharmacy has added these substances in an expedited regulatory process. A substance added via this process is removed from the schedule after 18 months unless a general law is enacted adding the substance to the schedule. This bill is identical to HB 193.

Bill Text

What changed in the latest version

774 added · 736 removed

Plain-language change summary

The latest version of SB 759 includes specific updates to the list of controlled substances under Schedule I of the Drug Control Act in Virginia. Notably, several new substances have been added, such as Brorphine and Metonitazene, while some existing descriptions were revised for clarity. These changes are important as they reflect updated evidence about harmful drugs, enhancing public safety by ensuring that more dangerous substances are properly regulated.

→
Previous
Latest
SESSION ENROLLED VIRGINIA ACTS OF ASSEMBLY –– CHAPTER E An Act to amend and reenact §§ 54.1-3446, 54.1-3448, 54.1-3452, and 54.1-3454 of the Code of N Virginia, relating to Drug Control Act;
VIRGINIA ACTS OF ASSEMBLY -- 2022 SESSION CHAPTER 115 An Act to amend and reenact §§ 54.1-3446, 54.1-3448, 54.1-3452, and 54.1-3454 of the Code of Virginia, relating to Drug Control Act;
R O [S 759] Approved L L Be it enacted by the General Assembly of Virginia:
[S 759] Approved April 6, 2022 Be it enacted by the General Assembly of Virginia:
That §§ 54.1-3446, 54.1-3448, 54.1-3452, and 54.1-3454 of the Code of Virginia are amended aEd reenacted as follows:
That §§ 54.1-3446, 54.1-3448, 54.1-3452, and 54.1-3454 of the Code of Virginia are amended and reenacted as follows:
D The controlled substances listed in this section are included in Schedule I:
§ 54.1-3446.
Schedule I.
The controlled substances listed in this section are included in Schedule I:
Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:
Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and1-{1-[1-(4-bromophenyl)ethyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one (other name:
1-{1-[1-(4-bromophenyl)ethyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one (other name:
2-methyl AP-23B);
2-methyl AP-237);
5 2-[(4-methoxyphenyl)methyl]-N,N-diethyl-5-nitro-1H-benzimidazole-1-ethanamine (other name:
1-methyl-4-phenyl-4-propionoxypiperidine (other name:
E Metonitazene);
MPPP);
R 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-aceta(other name:
2-[(4-methoxyphenyl)methyl]-N,N-diethyl-5-nitro-1H-benzimidazole-1-ethanamine (other name:
Metonitazene);
2-methoxy-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide (other name:
Allylprodine;
Betaprodine;
Dipipanone;butyrate;
Dioxaphetylbutyrate;
Dipipanone;
Morpheridine;orphan;
Levophenacylmorphan;
Morpheridine;
of 13 N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (other name:
N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (other name:
Tetrahydrofuranyl fentanyl);
Tetrahydrofuranyl of 13 fentanyl);
N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-(other name:
N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine (other name:
of 13 2-(3,4-dichlorophenyl)-N-[2-(dimethylamino)cyclohexyl]-N-methyl acetamide (other name:
2-(3,4-dichlorophenyl)-N-[2-(dimethylamino)cyclohexyl]-N-methyl acetamide (other name:
OcfeEtanil);
Ocfentanil);
N N-phenyl-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name:
N-phenyl-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name:
Isobutyryl feRtanyl);
Isobutyryl fentanyl);
N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-cyclopentanecarbox(other name:
of 13 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-cyclopentanecarboxamide (other name:
Cyclopentyl fenN-phenyl-N-(1-methyl-4-piperidinyl)-propanamide (other name:
Cyclopentyl fentanyl);
N-phenyl-N-(1-methyl-4-piperidinyl)-propanamide (other name:
O N-[2-(dimethylamino)cyclohexyl]-N-methyl-1,3-benzodioxole-5-carboxamide (other names:
N-[2-(dimethylamino)cyclohexyl]-N-methyl-1,3-benzodioxole-5-carboxamide (other names:
L 3,4-methylenedioxy U-47700 or 3,4-MDO-U-47700);
3,4-methylenedioxy U-47700 or 3,4-MDO-U-47700);
L N-phenyl-N-[4-phenyl-1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name:
N-phenyl-N-[4-phenyl-1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name:
4-phenylfentaEyl);
4-phenylfentanyl);
D N-[2-(dimethylamino)cyclohexyl]-N-phenylfuran-2-carboxamide (other name:
N-[2-(dimethylamino)cyclohexyl]-N-phenylfuran-2-carboxamide (other name:
U-47700).chloro-N-[2-(dimethylamino)cyclohexyl]-N-isopropyl-benzamide (other name:
3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-isopropyl-benzamide (other name:
Isopropyl 2.
Isopropyl U-47700).
2.
S Acetorphine;
Acetorphine;
7 Acetyldihydrocodeine;
Acetyldihydrocodeine;
Show all 182 changed rows (142 more)
Previous
Latest
9 Benzylmorphine;
Benzylmorphine;
R Codeine methylbromide;
Codeine methylbromide;
Desomorphine;
Myrophine;-Oxide;
Morphine-N-Oxide;
Myrophine;
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, only, the term "isomer" includes the optical, position, and geometric isomers):purposes of this subdivision Alpha-ethyltryptamine (some trade or other names:
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for purposes of this subdivision only, the term "isomer" includes the optical, position, and geometric isomers):
Alpha-ethyltryptamine (some trade or other names:
Diethyltryptamine;
of 13 2,5-dimethoxy-4-ethylamphetamine (DOET);
2,5-dimethoxy-4-ethylamphetamine (DOET);
3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo [b,d] pyran;
of 13 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo [b,d] pyran;
of 13 4-Ethylmethcathinone (other name:
4-Ethylmethcathinone (other name:
E Beta-keto-methylbenzodioxolylpentanamine (other names:
Beta-keto-methylbenzodioxolylpentanamine (other names:
N Alpha-methylamino-valerophenone (other name:
Alpha-methylamino-valerophenone (other name:
R 3,4-Dimethylmethcathinone (other name:
3,4-Dimethylmethcathinone (other name:
4-methyl-alpha-pyrrolidinopropiophenone (other name:
MPPP);
25-I, O 25I-NBOMe, 2C-I-NBOMe);
25-I, 25I-NBOMe, 2C-I-NBOMe);
L Methoxetamine (other names:
Methoxetamine (other names:
L 4-Fluoroamphetamine (other name:
of 13 4-Fluoroamphetamine (other name:
E 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (other name:
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (other name:
D 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (other name:
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (other name:
2-(2,5-Dimethoxyphenyl)ethanamine (other name:
2C-H);
S 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (other names:
4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (other names:
7 2C-C-NBOMe, 25C-NBOMe, 25C);
2C-C-NBOMe, 25C-NBOMe, 25C);
9 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (other names:
4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (other names:
R 2C-B-NBOMe, 25B-NBOMe, 25B);
2C-B-NBOMe, 25B-NBOMe, 25B);
Alpha-pyrrolidinobutiophenone (other name:
alpha-PBP);
1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-pentanone (other name:
N-ethylpentylone);
3-methoxy PCP);pentylone);
3-methoxy PCP);
1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-pentan(other names:
1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-pentanone (other names:
3,4-tetramethylene-alpha-pyrrolidinovalerophenone (other name:
TH-PVP);
Allylescaline);VP);
Allylescaline);
6-ethyl-6-nor-lysergic acid diethylamide (other name:
ETH-LAD);
AL-LAD);;
AL-LAD);
of 13 2-(methylamino)-2-phenyl-cyclohexanone (other name:
2-(methylamino)-2-phenyl-cyclohexanone (other name:
5-methoxy-N,N-dibutyltryptamine (other name:
of 13 5-methoxy-N,N-dibutyltryptamine (other name:
of 13 Aminorex (some trade or other names;
Aminorex (some trade or other names;
E Cathinone (some trade or other names:
Cathinone (some trade or other names:
R Ethylamphetamine;
Ethylamphetamine;
Fenethylline;piperidin-2-yl)acetate (other name:
Ethyl phenyl(piperidin-2-yl)acetate (other name:
O Methcathinone (some other names:
Fenethylline;
Methcathinone (some other names:
L alpha-(methylamino)-propiophenone;
alpha-(methylamino)-propiophenone;
L methylcathinone;
methylcathinone;
E N-Benzylpiperazine (some other names:
N-Benzylpiperazine (some other names:
N, N-alpha-trimethyl-benzeneethanamine, N, D N-alpha-trimethylphenethylamine) N,N-alpha-trimethyl-benzeneethanamine, N,N-alpha-trimethylphenethylamine);
N, N-alpha-trimethyl-benzeneethanamine, N, N-alpha-trimethylphenethylamine) N,N-alpha-trimethyl-benzeneethanamine, N,N-alpha-trimethylphenethylamine);
Isopropyl-2-phenyl-2-(2-piperidinyl)acetate (other name:
Methyl 2-(4-fluorophenyl)-2-(2-piperidinyl)acetate (other name:
Isopropylphenidate);lphenidate);
4-fluoromethylphenidate);
of 13 Isopropyl-2-phenyl-2-(2-piperidinyl)acetate (other name:
Isopropylphenidate);
Any substance that contains one or more cannabimimetic agents or that contains their saltS, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isome7s is possible within the specific chemical designation, and any preparation, mixture, or substance c9ntaining, or mixed or infused with, any detectable amount of one or more cannabimimetic agents.
Any substance that contains one or more cannabimimetic agents or that contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, and any preparation, mixture, or substance containing, or mixed or infused with, any detectable amount of one or more cannabimimetic agents.
R a.
a.
2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alk3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent;
2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent;
3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent;
whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent;
3-phenylacetylindole or 3-benzoylindole with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent;
N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring, adamantyl ring to any extent;
N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the adamantyl ring to any extent;
andd on the indole ring to any extent, whether or not substituted on the N-(adamantyl)-indazole-3-carboxamide with substitution at a nitrogen atom of the indazole ring, whether or not further substituted on the indazole ring to any extent, whether or not substituted on the adamantyl ring to any extent.
and N-(adamantyl)-indazole-3-carboxamide with substitution at a nitrogen atom of the indazole ring, whether or not further substituted on the indazole ring to any extent, whether or not substituted on the adamantyl ring to any extent.
1-butyl-3-(1-naphthoyl)indole (other name:
JWH-073);
of 13 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (other name:
1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (other name:
Pravadoline (4-methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indoll]methanone (other name:
Pravadoline (4-methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-y l]methanone (other name:
N-adamantyl-1-fluoropentylindole-3-carboxamide (other name:
of 13 N-adamantyl-1-fluoropentylindole-3-carboxamide (other name:
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxa(other name:
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (other name:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxam ide N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carbo(other names:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxam ide N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamid(other names:
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indaz3-carboxamide N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carb(othere name:
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole- 3-carboxamide N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamid(other name:
Methyl 2-[1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamido]-3methylbutanoate (other name:
Methyl 2-[1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamido]-3,3-dmethylbutanoate (other name:
Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbuean(other names:
Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoae (other names:
of 13 Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate (other name:
Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate (other name:
E AB-CHMICA);
AB-CHMICA);
N Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (other name:
Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (other name:
R Methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (other name:
Methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (other name:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide (other name:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamid e N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide (other name:
O 5-fluoro-ADB-PINACA);
5-fluoro-ADB-PINACA);
L 1-(4-cyanobutyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3-carboxamide (other name:
1-(4-cyanobutyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3-carboxamide (other name:
L Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoate (other name:
Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoate (other name:
E 5-Fluoro-MDMB-PICA) names:
5-Fluoro-MDMB-PICA) names:
Ethyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoat e Ethyl D 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (other name:
Ethyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoat e Ethyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (other name:
4-fluoro-MDMB-BUTINACA);utyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other name:
Methyl 2-[1-4-fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other name:
4-fluoro-MDMB-BUTINACA);
S MDMB-4en-PINACA);
MDMB-4en-PINACA);
7 Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indole-3-carbonyl}amino)-3-methylbutanoate (other n9mes:
Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indole-3-carbonyl}amino)-3-methylbutanoate (other names:
MMB-FUBICA, AMB-FUBICA);
of 13 MMB-FUBICA, AMB-FUBICA);
R Methyl 2-[1-(4-penten-1-yl)-1H-indole-3-carboxamido]-3-methylbutanoate (other names:
Methyl 2-[1-(4-penten-1-yl)-1H-indole-3-carboxamido]-3-methylbutanoate (other names:
5-fluoro-MPP-PICA);luoropentyl)-1H-indole-3-carboxamido]-3-phenylpropanoate (other name:
Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3-phenylpropanoate (other name:
5-fluoro-MPP-PICA);
5-fluoro-EMB-PINACA, 5F-AEB);)-1H-indazole-3-carboxamido]-3-methylbutanoate (other names:
Ethyl-2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (other names:
5-fluoro-EMB-PINACA, 5F-AEB);
Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbuta(other names:
Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (other names:
ADB-4en-PINACA).3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-enyl)indazole-3-carboxamide (other name:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-enyl)indazole-3-carboxamide (other name:
ADB-4en-PINACA).
Opium extracts;
of 13 Granulated opium;
Granulated opium;
2.
of 13 2.
of 13 Phenmetrazine and its salts;
Phenmetrazine and its salts;
Any substance which contains any quantity of methamphetamine, including its salts, isomers, End salts of isomers;
Any substance which contains any quantity of methamphetamine, including its salts, isomers, and salts of isomers;
N Lisdexamfetamine, its salts, isomers, and salts of its isomers.
Lisdexamfetamine, its salts, isomers, and salts of its isomers.
R 4.
4.
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
L Amobarbital;
Amobarbital;
L Secobarbital;
Secobarbital;
E Pentobarbital;
Pentobarbital;
D 5.
5.
marketing by the U.S.
Dronabinol ((-)-delta-9-trans tetrahydrocannabinol) in an oral solution in a drug product approved for marketing by the U.S.
Food and Drug Administration.ol) in an oral solution in a drug product approved for 6.
Food and Drug Administration.
6.
S Phenylacetone.
Phenylacetone.
7 b.
b.
9 1-phenylcyclohexylamine;
1-phenylcyclohexylamine;
R 1-piperidinocyclohexanecarbonitrile (other name:
1-piperidinocyclohexanecarbonitrile (other name:
The controlled substances listed in this section are included in Schedule IV unless specifically excepted or listed in another schedule:
§ 54.1-3452.
Schedule IV.
The controlled substances listed in this section are included in Schedule IV unless specifically of 13 excepted or listed in another schedule:
Bromazepam;;
Brexanolone;
Bromazepam;
Cloxazolam;;
Clotiazepam;
Cloxazolam;
Flurazepam;
of 13 Haloxazolam;
Haloxazolam;
Fenfluramine;
of 13 Fenfluramine;
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, of 13 or preparation which contains any quantity of the following substances, including their salts:
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including their salts:
E Eluxadoline (including its optical isomers and its salts, isomers, and salts of isomers);
Eluxadoline (including its optical isomers and its salts, isomers, and salts of isomers);
N 6.
Pentazocine.
The Board may except by regulation any compound, mixture, or preparation containing any depressant substance listed in subdivision 1 from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having O depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.
6.
L § 54.1-3454.
The Board may except by regulation any compound, mixture, or preparation containing any depressant substance listed in subdivision 1 from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.
§ 54.1-3454.
The controlled substances listed in this section are included in Schedule V:
grams;
Not more than 100 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or per 100 grams;
more than 100 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or pSr 100 Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;
Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;
5 Not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
Not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
E Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.
Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.
The Board may except by regulation any compound, mixture, or preparation containing any such substances so excepted may be dispensed pursuant to § 54.1-3416.all or any part of this chapter and 2.
The Board may except by regulation any compound, mixture, or preparation containing any depressant substance listed in subdivision 1 from the application of all or any part of this chapter and such substances so excepted may be dispensed pursuant to § 54.1-3416.
2.
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the cenBrivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also referred to as BRV;
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the of 13 central nervous system, including its salts:
Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also referred to as BRV;
commitment.
2.
Pursuant to § 30-19.1:4 of the Code of Virginia, the estimated amount of thent or necessary appropriation is $0 for periods of imprisonment in state adult correctional facilities and $0 for periods of commitment to the custody of the Department of Juvenile Justice.
That the provisions of this act may result in a net increase in periods of imprisonment or commitment.
Pursuant to § 30-19.1:4 of the Code of Virginia, the estimated amount of the necessary appropriation is $0 for periods of imprisonment in state adult correctional facilities and $0 for periods of commitment to the custody of the Department of Juvenile Justice.
View plain text versions (3)
  • CHAP0115 View text Current pdf April 06, 2022
  • SB759ER View text pdf March 01, 2022
  • Presented and ordered printed 22104959D View text pdf January 21, 2022

Action History

  1. Approved by Governor-Chapter 115 (effective 7/1/22)

  2. Governor's Action Deadline 11:59 p.m., April 11, 2022

  3. Enrolled Bill Communicated to Governor on March 11, 2022

  4. Signed by President

  5. Signed by Speaker

  6. Impact statement from DPB (SB759ER)

  7. Enrolled

  8. VOTE: Passage (91-Y 7-N)

  9. Passed House (91-Y 7-N)

  10. Read third time

  11. Read second time

  12. Reported from Health, Welfare and Institutions (18-Y 2-N)

  13. Referred to Committee on Health, Welfare and Institutions

  14. Read first time

  15. Placed on Calendar

  16. Passed Senate (40-Y 0-N)

  17. Reconsideration of passage agreed to by Senate (40-Y 0-N)

  18. Read third time and passed Senate (39-Y 0-N)

  19. Read second time and engrossed

  20. Constitutional reading dispensed (39-Y 0-N)

  21. Reported from Education and Health (15-Y 0-N)

  22. Impact statement from DPB (SB759)

  23. Impact statement from VCSC (SB759)

  24. Referred to Committee on Education and Health

  25. Presented and ordered printed 22104959D

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 147 not signed on · 7 voted No

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (147)

147 members have not signed on to this bill.

Show all 147 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

VOTE: Passage (91-Y 7-N)

Passed 90 Yea · 7 Nay · 2 Other
Party YeaNayPresentNot Voting
Unaffiliated 90702
Total 90702
% of votes cast 91%7%0%2%
How each member voted (99)
Member Party Vote
Greenhalgh, Karen S. — Yea
March, Marie E. — Yea
Adams, Dawn M. — Not Voting
Adams, Les R. — Yea
Alfonso H. Lopez — Yea
Angelia Williams Graves — Nay
Anne Ferrell Tata — Yea
Avoli, G. "John" — Yea
Batten, Amanda E. — Yea
Bell, Robert B. — Yea
Betsy B. Carr — Yea
Bill Wiley — Yea
Bourne, Jeffrey M. — Yea
Briana D. Sewell — Yea
Bulova, David L. — Yea
Byron, Kathy J. — Yea
C.E. Cliff Hayes, Jr. — Yea
Campbell, Jeffrey L. — Yea
Campbell, Ronnie R. — Yea
Charniele L. Herring — Yea
Chris S. Runion — Yea
Christopher T. Head — Yea
Convirs-Fowler, Kelly K. — Not Voting
Cordoza, A.C. — Yea
Coyner, Carrie E. — Yea
Dan I. Helmer — Yea
Danica A. Roem — Yea
David A. Reid — Yea
Davis, Glenn R. — Yea
Delores L. McQuinn — Yea
Don Scott — Nay
Edmunds, James E., II — Yea
Elizabeth B. Bennett-Parker — Yea
Emily M. Jordan — Yea
Fariss, C. Matthew — Yea
Filler-Corn, Eileen — Yea
Fowler, Hyland F."Buddy," Jr. — Yea
Freitas, Nicholas J. — Yea
Gooditis, Wendy W. — Yea
Guzman, Elizabeth R. — Yea
H. Otto Wachsmann, Jr. — Yea
Hudson, Sally L. — Nay
Irene Shin — Yea
Israel D. O'Quinn — Yea
Jackie H. Glass — Nay
James A. "Jay" Leftwich — Yea
James W. Morefield — Yea
Jason S. Ballard — Yea
Jeion A. Ward — Yea
Jenkins, Clinton L. — Yea
Jessica L. Anderson — Yea
Joseph P. McNamara — Yea
Karrie K. Delaney — Yea
Kathy K.L. Tran — Yea
Keam, Mark L. — Yea
Knight, Barry D. — Yea
Kory, Kaye — Yea
LaRock, Dave A. — Yea
Lamont Bagby — Yea
Luke E. Torian — Yea
M. Keith Hodges — Yea
Maldonado, Michelle Lopes — Yea
Marcia S. "Cia" Price — Nay
Marcus B. Simon — Yea
Marshall, Daniel W., III — Yea
McGuire, John J., III — Yea
Michael J. Webert — Yea
Mike A. Cherry — Yea
Mullin, Michael P. — Yea
Mundon King, Candi — Nay
Murphy, Kathleen — Yea
Nadarius E. Clark — Nay
Orrock, Robert D., Sr. — Yea
Patrick A. Hope — Yea
Paul E. Krizek — Yea
Phillip A. Scott — Yea
Plum, Kenneth R. — Yea
R. Lee Ware — Yea
Ransone, Margaret B. — Yea
Richard C. "Rip" Sullivan, Jr. — Yea
Robert S. Bloxom, Jr. — Yea
Robinson, Roxann L. — Yea
Rodney T. Willett — Yea
Sam Rasoul — Yea
Schuyler T. VanValkenburg — Yea
Scott A. Wyatt — Yea
Shelly A. Simonds — Yea
Sickles, Mark D. — Yea
Subramanyam, Suhas — Yea
Tara A. Durant — Yea
Taylor, Kim A. — Yea
Terry G. Kilgore — Yea
Terry L. Austin — Yea
Thomas C. Wright, Jr. — Yea
Tony O. Wilt — Yea
Vivian E. Watts — Yea
Wampler, William C., III — Yea
Wendell S. Walker — Yea
Wren M. Williams — Yea

Official roll call →

Passed 18 Yea · 2 Nay · 2 Other
Party YeaNayPresentNot Voting
Unaffiliated 18202
Total 18202
% of votes cast 82%9%0%9%
How each member voted (22)

Official roll call →

Passed 40 Yea · 0 Nay
Party YeaNayPresentNot Voting
Unaffiliated 40000
Total 40000
% of votes cast 100%0%0%0%
How each member voted (40)
Member Party Vote
McClellan, Jennifer L. — Yea
Morrissey, Joseph D. — Yea
Spruill, Lionell, Sr. — Yea
Barbara A. Favola — Yea
Barker, George L. — Yea
Bell, John J. — Yea
Bill DeSteph — Yea
Bryce E. Reeves — Yea
Chase, Amanda F. — Yea
Cosgrove, John A., Jr. — Yea
David R. Suetterlein — Yea
David W. Marsden — Yea
Dunnavant, Siobhan S. — Yea
Ebbin, Adam P. — Yea
Edwards, John S. — Yea
Hanger, Emmett W., Jr. — Yea
Hashmi, Ghazala F. — Yea
Howell, Janet D. — Yea
Jennifer B. Boysko — Yea
Jeremy S. McPike — Yea
Kiggans, Jennifer A. — Yea
L. Louise Lucas — Yea
Lewis, Lynwood W., Jr. — Yea
Mamie E. Locke — Yea
Mark D. Obenshain — Yea
Mark J. Peake — Yea
Mason, T. Montgomery "Monty" — Yea
Newman, Stephen D. — Yea
Norment, Thomas K., Jr. — Yea
Petersen, J. Chapman — Yea
R. Creigh Deeds — Yea
Richard H. Stuart — Yea
Ruff, Frank M., Jr. — Yea
Ryan T. McDougle — Yea
Saslaw, Richard L. — Yea
Scott A. Surovell — Yea
T. Travis Hackworth — Yea
Todd E. Pillion — Yea
Vogel, Jill Holtzman — Yea
William M. Stanley, Jr. — Yea

Official roll call →

Passed Senate (40-Y 0-N)

Passed 40 Yea · 0 Nay
Party YeaNayPresentNot Voting
Unaffiliated 40000
Total 40000
% of votes cast 100%0%0%0%
How each member voted (40)
Member Party Vote
McClellan, Jennifer L. — Yea
Morrissey, Joseph D. — Yea
Spruill, Lionell, Sr. — Yea
Barbara A. Favola — Yea
Barker, George L. — Yea
Bell, John J. — Yea
Bill DeSteph — Yea
Bryce E. Reeves — Yea
Chase, Amanda F. — Yea
Cosgrove, John A., Jr. — Yea
David R. Suetterlein — Yea
David W. Marsden — Yea
Dunnavant, Siobhan S. — Yea
Ebbin, Adam P. — Yea
Edwards, John S. — Yea
Hanger, Emmett W., Jr. — Yea
Hashmi, Ghazala F. — Yea
Howell, Janet D. — Yea
Jennifer B. Boysko — Yea
Jeremy S. McPike — Yea
Kiggans, Jennifer A. — Yea
L. Louise Lucas — Yea
Lewis, Lynwood W., Jr. — Yea
Mamie E. Locke — Yea
Mark D. Obenshain — Yea
Mark J. Peake — Yea
Mason, T. Montgomery "Monty" — Yea
Newman, Stephen D. — Yea
Norment, Thomas K., Jr. — Yea
Petersen, J. Chapman — Yea
R. Creigh Deeds — Yea
Richard H. Stuart — Yea
Ruff, Frank M., Jr. — Yea
Ryan T. McDougle — Yea
Saslaw, Richard L. — Yea
Scott A. Surovell — Yea
T. Travis Hackworth — Yea
Todd E. Pillion — Yea
Vogel, Jill Holtzman — Yea
William M. Stanley, Jr. — Yea

Official roll call →

Passed 39 Yea · 0 Nay · 1 Other
Party YeaNayPresentNot Voting
Unaffiliated 39001
Total 39001
% of votes cast 98%0%0%3%
How each member voted (40)
Member Party Vote
McClellan, Jennifer L. — Yea
Morrissey, Joseph D. — Yea
Spruill, Lionell, Sr. — Yea
Barbara A. Favola — Yea
Barker, George L. — Yea
Bell, John J. — Not Voting
Bill DeSteph — Yea
Bryce E. Reeves — Yea
Chase, Amanda F. — Yea
Cosgrove, John A., Jr. — Yea
David R. Suetterlein — Yea
David W. Marsden — Yea
Dunnavant, Siobhan S. — Yea
Ebbin, Adam P. — Yea
Edwards, John S. — Yea
Hanger, Emmett W., Jr. — Yea
Hashmi, Ghazala F. — Yea
Howell, Janet D. — Yea
Jennifer B. Boysko — Yea
Jeremy S. McPike — Yea
Kiggans, Jennifer A. — Yea
L. Louise Lucas — Yea
Lewis, Lynwood W., Jr. — Yea
Mamie E. Locke — Yea
Mark D. Obenshain — Yea
Mark J. Peake — Yea
Mason, T. Montgomery "Monty" — Yea
Newman, Stephen D. — Yea
Norment, Thomas K., Jr. — Yea
Petersen, J. Chapman — Yea
R. Creigh Deeds — Yea
Richard H. Stuart — Yea
Ruff, Frank M., Jr. — Yea
Ryan T. McDougle — Yea
Saslaw, Richard L. — Yea
Scott A. Surovell — Yea
T. Travis Hackworth — Yea
Todd E. Pillion — Yea
Vogel, Jill Holtzman — Yea
William M. Stanley, Jr. — Yea

Official roll call →

Passed 39 Yea · 0 Nay · 1 Other
Party YeaNayPresentNot Voting
Unaffiliated 39001
Total 39001
% of votes cast 98%0%0%3%
How each member voted (40)
Member Party Vote
McClellan, Jennifer L. — Yea
Morrissey, Joseph D. — Yea
Spruill, Lionell, Sr. — Yea
Barbara A. Favola — Yea
Barker, George L. — Yea
Bell, John J. — Yea
Bill DeSteph — Yea
Bryce E. Reeves — Yea
Chase, Amanda F. — Yea
Cosgrove, John A., Jr. — Yea
David R. Suetterlein — Yea
David W. Marsden — Yea
Dunnavant, Siobhan S. — Yea
Ebbin, Adam P. — Yea
Edwards, John S. — Yea
Hanger, Emmett W., Jr. — Yea
Hashmi, Ghazala F. — Yea
Howell, Janet D. — Yea
Jennifer B. Boysko — Yea
Jeremy S. McPike — Yea
Kiggans, Jennifer A. — Yea
L. Louise Lucas — Yea
Lewis, Lynwood W., Jr. — Yea
Mamie E. Locke — Yea
Mark D. Obenshain — Yea
Mark J. Peake — Yea
Mason, T. Montgomery "Monty" — Yea
Newman, Stephen D. — Yea
Norment, Thomas K., Jr. — Yea
Petersen, J. Chapman — Yea
R. Creigh Deeds — Yea
Richard H. Stuart — Yea
Ruff, Frank M., Jr. — Yea
Ryan T. McDougle — Yea
Saslaw, Richard L. — Yea
Scott A. Surovell — Yea
T. Travis Hackworth — Yea
Todd E. Pillion — Yea
Vogel, Jill Holtzman — Not Voting
William M. Stanley, Jr. — Yea

Official roll call →

Passed 15 Yea · 0 Nay
Party YeaNayPresentNot Voting
Unaffiliated 15000
Total 15000
% of votes cast 100%0%0%0%
How each member voted (15)

Official roll call →

Subjects

Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SB 759 do?
Drug Control Act; Schedule I; Schedule II; Schedule IV; Schedule V. Adds certain chemicals to the Drug Control Act. The Board of Pharmacy has added these substances in an expedited regulatory process. A substance added via this process is removed from the schedule after 18 months unless a general law is enacted adding the substance to the schedule. This bill is identical to HB 193.
Who sponsors SB 759?
SB 759 is sponsored by Newman, Stephen D..
What is the current status of SB 759?
This bill has been enacted into law. Introduced January 21, 2022. Enacted.
Where can I track SB 759?
Track SB 759 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 759

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Stay ahead of SB 759

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →